对256例服用吉非替尼非小细胞肺癌患者的药学监护体会

The experience of pharmacological monitoring of 256 non-small cell lung cancer patients taking gefitinib

目的探讨对256例服用吉非替尼非小细胞肺癌患者实施药学监护的过程、方法及其作用。方法选取2017年10月至2019年10月在我院肿瘤科住院的服用吉非替尼的非小细胞肺癌患者256例,对照组给予常规药物治疗,观察组在药物治疗基础上给予针对性药学监护措施,对其不良反应相应给予不同的应对方案,整理、归纳和分析两组的治疗总有效率、不良反应总发生率和因不良反应导致的总停药率。结果观察组的治疗总有效率为48.44%,明显高于对照组的28.12%,差异有统计学意义(P<0.05);两组不良反应总发生率比较,差异无统计学意义(P>0.05);观察组因不良反应导致的总停药率为25.78%,明显低于对照组的40.63%,差异有统计学意义(P<0.05)。结论通过对吉非替尼不良反应的针对性药学监护,使其疗效显著升高、停药率显著降低,大大提高了患者的依从性。

Objective To explore the process,method and effect of pharmacological monitoring on 256 non-small cell lung cancer patients taking gefitinib.Methods A total of 256 non-small cell lung cancer patients taking gefitinib who were admitted to the oncology department of our hospital from October 2017 to October 2019 were selected.The control group was given conventional drug treatment.The observation group was given targeted pharmaceutical monitoring measures on the basis of conventional drug treatment.Different countermeasures were given for corresponding adverse reactions.The total effective rate,incidence of total adverse reactions,and the total discontinuation rates due to adverse reactions were sorted out,summarized,and analyzed in the two groups.Results The total effective rate of treatment in the observation group(48.44%)was significantly higher than that of the control group(28.12%),and the difference was statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).The total discontinuation rate of the observation group(25.78%)due to the occurrence of adverse reactions was significantly lower than that of the control group(40.63%),and the difference was statistically significant(P<0.05).Conclusion Through targeted pharmacological monitoring of adverse reactions to gefitinib,the efficacy of treatment was significantly improved,the rate of withdrawal was significantly reduced,and the patient compliance was greatly improved.